Opinion|Videos|May 12, 2025
Choosing Wisely: Insights from an MAIC and eXalt3
Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).
Advertisement
Episodes in this series
Comparative Data Analysis and Ensartinib Approval
Key Themes:
- Matching-adjusted indirect comparisons (MAIC) of lorlatinib versus alectinib or brigatinib
- Overview of the eXalt3 study for ensartinib
- Implications of ensartinib’s December 2024 FDA approval
Notable Insights:
- Dr Dietrich analyzed insights from the MAIC of lorlatinib versus other ALK inhibitors
Dr Lovly provided an overview of the eXalt3 study following ensartinib’s recent FDA approval in December 2024
Advertisement
Related to this article
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Inside the CAR T-Cell Therapy Process for CLL
5